Skip to main content

Advertisement

SpringerLink
Log in

Immunology and immunotherapy in gastric cancer

  • Review
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. As the diagnosis of early gastric cancer is difficult, most patients are at a late stage of cancer progression when diagnosed. The current therapeutic approaches based on surgical or endoscopic resection and chemotherapy indeed improve patients’ outcomes. Immunotherapy based on immune checkpoint inhibitors has opened a new era for cancer treatment, and the immune system of the host is reshaped to combat tumor cells and the strategy differs according to the patient’s immune system. Thus, an in-depth understanding of the roles of various immune cells in the progression of gastric cancer is beneficial to application for immunotherapy and the discovery of new therapeutic targets. This review describes the functions of different immune cells in gastric cancer development, mainly focusing on T cells, B cells, macrophages, natural killer cells, dendritic cells, neutrophils as well as chemokines or cytokines secreted by tumor cells. And this review also discusses the latest advances in immune-related therapeutic approaches such as immune checkpoint inhibitors, CAR-T or vaccine, to reveal potential and promising strategies for gastric cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778–89.

    CAS  Google Scholar 

  2. Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, et al. Early gastric cancer: update on prevention, diagnosis and treatment. Int J Environ Res Public Health. 2023;20:2149.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Ono H, Yao K, Fujishiro M, Oda I, Uedo N, Nimura S, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). Dig Endosc. 2021;33:4–20.

    PubMed  Google Scholar 

  4. Jiang L, Yang KH, Guan QL, Chen Y, Zhao P, et al. Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis. J Clin Gastroenterol. 2015;49:387–94.

    CAS  PubMed  Google Scholar 

  5. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79:4557–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Högner A, Moehler M. Immunotherapy in gastric cancer. Curr Oncol. 2022;29(3):1559–74.

    PubMed  PubMed Central  Google Scholar 

  9. van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20:218–32.

    PubMed  PubMed Central  Google Scholar 

  10. He W, Zhang H, Han F, Chen X, Lin R, Wang W, et al. CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 2017;77:6375–88.

    CAS  PubMed  Google Scholar 

  11. El-Zaatari M, Bishu S, Zhang M, Grasberger H, Hou G, Haley H, et al. Aim2-mediated/IFN-beta-independent regulation of gastric metaplastic lesions via CD8+ T cells. JCI Insight. 2020. https://doi.org/10.1172/jci.insight.94035.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lin F, Dai C, Ge X, Tang W, Lin Y, Wang Y, et al. Prognostic significance and functional implication of immune activating receptor NKG2D in gastric cancer. Biochem Biophys Res Commun. 2017;487:619–24.

    CAS  PubMed  Google Scholar 

  13. Lin R, Zhang H, Yuan Y, He Q, Zhou J, Li S, et al. Fatty acid oxidation controls CD8(+) tissue-resident memory T-cell survival in gastric adenocarcinoma. Cancer Immunol Res. 2020;8:479–92.

    CAS  PubMed  Google Scholar 

  14. Poffenberger MC, Metcalfe-Roach A, Aguilar E, Chen J, Hsu BE, Wong AH, et al. LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis. Science. 2018;361:406–11.

    CAS  PubMed  Google Scholar 

  15. Kwak Y, Koh J, Park Y, Hong YJ, Park KU, Kim HH, et al. Differential prognostic impact of CD8(+) T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer. Br J Cancer. 2020;122:1399–408.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Jin K, Cao Y, Gu Y, Fang H, Fei Y, Wang J, et al. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. Oncoimmunology. 2021;10:1915560.

    PubMed  PubMed Central  Google Scholar 

  17. Wang J, Li R, Cao Y, Gu Y, Fang H, Fei Y, et al. Intratumoral CXCR5(+)CD8(+)T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. Nat Commun. 2021;12:3080.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. He X, Gu Y, Cao Y, Hu B, Fang H, Fei Y, et al. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. Eur J Cancer. 2021;157:114–23.

    CAS  PubMed  Google Scholar 

  19. Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, et al. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer. 2020;23:73–81.

    CAS  PubMed  Google Scholar 

  20. Kim Y, Rhee YY, Wen X, Cho NY, Bae JM, Kim WH, et al. Combination of L1 methylation and tumor-infiltrating lymphocytes as prognostic marker in advanced gastric cancer. Gastric Cancer. 2020;23:464–72.

    CAS  PubMed  Google Scholar 

  21. Chen K, Gu Y, Cao Y, Fang H, Lv K, Liu X, et al. TIM3(+) cells in gastric cancer: clinical correlates and association with immune context. Br J Cancer. 2022;126:100–8.

    CAS  PubMed  Google Scholar 

  22. Park Y, Seo AN, Koh J, Nam SK, Kwak Y, Ahn SH, et al. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. Oncoimmunology. 2021;10:1954761.

    PubMed  PubMed Central  Google Scholar 

  23. Wang J, Lin C, Li H, Li R, Wu Y, Liu H, et al. Tumor-infiltrating gamma delta T cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. Oncoimmunology. 2017;6:e1353858.

    PubMed  PubMed Central  Google Scholar 

  24. Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794–801.

    CAS  PubMed  Google Scholar 

  25. Zhou X, Fang D, Liu H, Ou X, Zhang C, Zhao Z, et al. PMN-MDSCs accumulation induced by CXCL1 promotes CD8(+) T cells exhaustion in gastric cancer. Cancer Lett. 2022;532: 215598.

    CAS  PubMed  Google Scholar 

  26. Song J, Yang R, Wei R, Du Y, He P, Liu X. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction. Mol Med. 2022;28:47.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K, et al. ICOS(+) Foxp3(+) TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686–95.

    CAS  PubMed  Google Scholar 

  28. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.

    PubMed  Google Scholar 

  29. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911.

    CAS  PubMed  Google Scholar 

  30. Kindlund B, Sjoling A, Yakkala C, Adamsson J, Janzon A, Hansson LE, et al. CD4(+) regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-beta. Gastric Cancer. 2017;20:116–25.

    CAS  PubMed  Google Scholar 

  31. Zhu F, Yi G, Liu X, Zhu F, Zhao A, Wang A, et al. Ring finger protein 31-mediated atypical ubiquitination stabilizes forkhead box P3 and thereby stimulates regulatory T-cell function. J Biol Chem. 2018;293:20099–111.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Fei Y, Cao Y, Gu Y, Fang H, Chen Y, Wang J, et al. Intratumoral Foxp3(+)RORgammat(+) T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients. Cancer Immunol Immunother. 2022;71:1–11.

    CAS  PubMed  Google Scholar 

  33. Qu Y, Wang X, Bai S, Niu L, Zhao G, Yao Y, et al. The effects of TNF-alpha/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer. Int J Cancer. 2022;150:1373–91.

    CAS  PubMed  Google Scholar 

  34. Mao FY, Kong H, Zhao YL, Peng LS, Chen W, Zhang JY, et al. Increased tumor-infiltrating CD45RA(−)CCR7(−) regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress. Cell Death Dis. 2017;8:e3002.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, et al. An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity. 2020;53:187 e8 203-e8.

    Google Scholar 

  36. Liu X, Xu D, Huang C, Guo Y, Wang S, Zhu C, et al. Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies. J Transl Med. 2019;17:192.

    PubMed  PubMed Central  Google Scholar 

  37. Chang WH, Lai AG. Aberrations in Notch-Hedgehog signalling reveal cancer stem cells harbouring conserved oncogenic properties associated with hypoxia and immunoevasion. Br J Cancer. 2019;121:666–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116:9999–10008.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Sequeira I, Neves JF, Carrero D, Peng Q, Palasz N, Liakath-Ali K, et al. Immunomodulatory role of Keratin 76 in oral and gastric cancer. Nat Commun. 2018;9:3437.

    PubMed  PubMed Central  Google Scholar 

  40. Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15:441–51.

    CAS  PubMed  Google Scholar 

  41. Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017;14:662–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Ni Z, Xing D, Zhang T, Ding N, Xiang D, Zhao Z, et al. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer. Immunol Res. 2021;69:43–52.

    CAS  PubMed  Google Scholar 

  43. Li Y, Wang HC, Wang JS, Sun B, Li LP. Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer. FEBS Open Bio. 2020;10:1149–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36–50.

    CAS  PubMed  Google Scholar 

  45. Li XL, Liu R, Su X, Pan YS, Han XF, Shao CS, et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Mol Cancer. 2019. https://doi.org/10.1186/s12943-019-1102-3.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Chen YL, Zhang SY, Wang QZ, Zhang XB. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017. https://doi.org/10.1186/s13045-017-0408-0.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lin C, He HY, Liu H, Li RC, Chen YF, Qi YY, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019;68:1764–73.

    CAS  PubMed  Google Scholar 

  48. Eissmann MF, Dijkstra C, Jarnicki A, Phesse T, Brunnberg J, Poh AR, et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. Nat Commun. 2019;10:2735.

    PubMed  PubMed Central  Google Scholar 

  49. Wang HC, Chen CW, Yang CL, Tsai IM, Hou YC, Chen CJ, et al. Tumor-associated macrophages promote epigenetic silencing of gelsolin through DNA methyltransferase 1 in gastric cancer cells. Cancer Immunol Res. 2017;5:885–97.

    CAS  PubMed  Google Scholar 

  50. Jeremiasen M, Borg D, Hedner C, Svensson M, Nodin B, Leandersson K, et al. Tumor-Associated CD68(+), CD163(+), and MARCO(+) macrophages as prognostic biomarkers in patients with treatment-naive gastroesophageal adenocarcinoma. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.534761.

    Article  PubMed Central  Google Scholar 

  51. Peng LS, Zhang JY, Teng YS, Zhao YL, Wang TT, Mao FY, et al. Tumor-associated monocytes/macrophages impair NK-cell function via TGFbeta1 in human gastric cancer. Cancer Immunol Res. 2017;5:248–56.

    CAS  PubMed  Google Scholar 

  52. Emami F, Pathak S, Nguyen TT, Shrestha P, Maharjan S, Kim JO, et al. Photoimmunotherapy with cetuximab-conjugated gold nanorods reduces drug resistance in triple negative breast cancer spheroids with enhanced infiltration of tumor-associated macrophages. J Control Release. 2021;329:645–64.

    CAS  PubMed  Google Scholar 

  53. Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest. 2019;129:1278–94.

    PubMed  PubMed Central  Google Scholar 

  54. Yu S, Li Q, Yu Y, Cui Y, Li W, Liu T, et al. Activated HIF1alpha of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer. Cancer Immunol Immunother. 2020;69:1973–87.

    CAS  PubMed  Google Scholar 

  55. Liu X, Cao Y, Li R, Gu Y, Chen Y, Qi Y, et al. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer. Eur J Cancer. 2020;128:27–37.

    CAS  PubMed  Google Scholar 

  56. Zhang H, Li R, Cao Y, Gu Y, Lin C, Liu X, et al. Poor clinical outcomes and immunoevasive contexture in intratumoral IL-10-producing macrophages enriched gastric cancer patients. Ann Surg. 2022;275:e626–35.

    PubMed  Google Scholar 

  57. Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23:90–105.

    CAS  PubMed  Google Scholar 

  58. Fuertes MB, Domaica CI, Zwirner NW. Leveraging NKG2D ligands in immuno-oncology. Front Immunol. 2021;12:713158.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88:577–83.

    CAS  PubMed  Google Scholar 

  60. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001;96:574–8.

    CAS  PubMed  Google Scholar 

  61. Saito H, Takaya S, Osaki T, Ikeguchi M. Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. Gastric Cancer. 2013;16:473–9.

    CAS  PubMed  Google Scholar 

  62. Li T, Zhang Q, Jiang Y, Yu J, Hu Y, Mou T, et al. Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. Oncoimmunology. 2015;5:e1069936.

    PubMed  PubMed Central  Google Scholar 

  63. Guo Z, Zhou C, Zhou L, Wang Z, Zhu X, Mu X. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer. Cell Immunol. 2022;372:104469.

    CAS  PubMed  Google Scholar 

  64. Lee SC, Shimasaki N, Lim JSJ, Wong A, Yadav K, Yong WP, et al. Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers. Clin Cancer Res. 2020;26:4494–502.

    CAS  PubMed  Google Scholar 

  65. Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, Nakao Y, Harada K, et al. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. Br J Cancer. 2021;124:595–603.

    CAS  PubMed  Google Scholar 

  66. Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020;8:e000450.

    PubMed  PubMed Central  Google Scholar 

  67. Xie MZ, Tang YP, Hu BL, Li KZ, Li JL, Liang XQ. Percentage of natural killer (NK) cells in peripheral blood is associated with prognosis in patients with gastric cancer: a retrospective study from a single center. Med Sci Monit. 2021;27:e927464.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Guo S, Huang C, Han F, Chen B, Ding Y, Zhao Y, et al. Gastric cancer mesenchymal stem cells inhibit NK cell function through mTOR signalling to promote tumour growth. Stem Cells Int. 2021;2021:9989790.

    PubMed  PubMed Central  Google Scholar 

  69. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Hargadon KM. Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol. 2013;4:192.

    PubMed  PubMed Central  Google Scholar 

  71. Okita Y, Tanaka H, Ohira M, Muguruma K, Kubo N, Watanabe M, et al. Role of tumor-infiltrating CD11b+ antigen-presenting cells in the progression of gastric cancer. J Surg Res. 2014;186:192–200.

    CAS  PubMed  Google Scholar 

  72. Yang J, Liu X, Cheng Y, Zhang J, Ji F, Ling Z. Roles of Plasmacytoid Dendritic Cells in Gastric Cancer. Front Oncol. 2022;12:818314.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Bai X, Wong CC, Pan Y, Chen H, Liu W, Zhai J, et al. Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J Immunother Cancer. 2022;10(2):e003663.

    PubMed  PubMed Central  Google Scholar 

  74. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528:413–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Wang TT, Zhao YL, Peng LS, Chen N, Chen W, Lv YP, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66:1900–11.

    CAS  PubMed  Google Scholar 

  77. Rayes RF, Mouhanna JG, Nicolau I, Bourdeau F, Giannias B, Rousseau S, et al. Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects. JCI Insight 2019; 5.

  78. Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 2018;17:146.

    PubMed  PubMed Central  Google Scholar 

  79. Li TJ, Jiang YM, Hu YF, Huang L, Yu J, Zhao LY, et al. Interleukin-17-producing neutrophils link inflammatory stimuli to disease progression by promoting angiogenesis in gastric cancer. Clin Cancer Res. 2017;23:1575–85.

    CAS  PubMed  Google Scholar 

  80. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71.

    CAS  PubMed  Google Scholar 

  81. Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, et al. Blockade of beta-catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration. Cancer Res. 2020;80:2004–16.

    CAS  PubMed  Google Scholar 

  82. Deswaerte V, Nguyen P, West A, Browning AF, Yu L, Ruwanpura SM, Balic J, et al. Inflammasome adaptor ASC suppresses apoptosis of gastric cancer cells by an IL18-mediated inflammation-independent mechanism. Cancer Res. 2018;78:1293–307.

    CAS  PubMed  Google Scholar 

  83. Chen Y, Chen B, Yang T, Xiao W, Qian L, Ding Y, et al. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells. Cell Mol Immunol. 2017;14:293–307.

    CAS  PubMed  Google Scholar 

  84. Sun L, Wang Q, Chen B, Zhao Y, Shen B, Wang X, et al. Human gastric cancer mesenchymal stem cell-derived IL15 contributes to tumor cell epithelial-mesenchymal transition via upregulation Tregs ratio and PD-1 expression in CD4(+)T cell. Stem Cells Dev. 2018;27:1203–14.

    CAS  PubMed  Google Scholar 

  85. Wang JT, Li H, Zhang H, Chen YF, Cao YF, Li RC, et al. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2019;30:266–73.

    CAS  PubMed  Google Scholar 

  86. Bie Q, Song H, Chen X, Yang X, Shi S, Zhang L, et al. IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination. Oncogene. 2021;40:2200–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Fang H, Li R, Gu Y, Fei Y, Jin K, Chen Y, et al. Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response. Oncoimmunology. 2020;9:1856468.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther. 2021;219:107694.

    CAS  PubMed  Google Scholar 

  89. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–40.

    PubMed  PubMed Central  Google Scholar 

  90. Zhou YJ, Zhu GQ, Lu XF, Zheng KI, Wang QW, Chen JN, et al. Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. Cancer Immunol Immunother. 2020;69:1057–69.

    CAS  PubMed  Google Scholar 

  91. Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23:565–78.

    CAS  PubMed  Google Scholar 

  92. Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, et al. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer. 2019;22:817–27.

    CAS  PubMed  Google Scholar 

  93. Park Y, Koh J, Na HY, Kwak Y, Lee KW, Ahn SH, et al. PD-L1 Testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat. 2020;52:661–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, et al. Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score >/=10. Clin Cancer Res. 2021;27:1923–31.

    CAS  PubMed  Google Scholar 

  95. Junttila A, Helminen O, Vayrynen JP, Ahtiainen M, Kenessey I, Jalkanen S, et al. Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer. Br J Cancer. 2020;123:1625–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Ohmura H, Yamaguchi K, Hanamura F, Ito M, Makiyama A, Uchino K, et al. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br J Cancer. 2020;122:1507–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Ying L, Yan F, Meng Q, Yu L, Yuan X, Gantier MP, et al. PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers. Oncoimmunology. 2018;7:e1433520.

    PubMed  PubMed Central  Google Scholar 

  98. Sundar R, Huang KK, Qamra A, Kim KM, Kim ST, Kang WK, et al. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Ann Oncol. 2019;30:424–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun. 2019;10:1336.

    PubMed  PubMed Central  Google Scholar 

  100. O’Reilly LA, Putoczki TL, Mielke LA, Low JT, Lin A, Preaudet A, et al. Loss of NF-kappaB1 causes gastric cancer with aberrant inflammation and expression of immune checkpoint regulators in a STAT-1-dependent manner. Immunity. 2018;48:570e8-583e8.

    Google Scholar 

  101. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer. 2021;24:946–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234–47.

    CAS  PubMed  Google Scholar 

  104. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38:2053–61.

    CAS  PubMed  Google Scholar 

  105. Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020;137:272–84.

    CAS  PubMed  Google Scholar 

  106. Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, et al. Targeting VEGFR2 with Ramucirumab strongly impacts effector/activated regulatory T cells and CD8(+) T cells in the tumor microenvironment. J Immunother Cancer. 2018;6:106.

    PubMed  PubMed Central  Google Scholar 

  107. Anjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:821–31.

    Google Scholar 

  108. Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, et al. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2020;23:143–53.

    CAS  PubMed  Google Scholar 

  109. Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b–2 trial. Lancet Oncol. 2020;21:1066–76.

    CAS  PubMed  Google Scholar 

  110. Lei M, Siemers NO, Pandya D, Chang H, Sanchez T, Harbison C, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab +/− ipilimumab in gastric cancer/gastroesophageal junction cancer. Clin Cancer Res. 2021;27:3926–35.

    CAS  PubMed  Google Scholar 

  111. D’Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab. Clin Cancer Res. 2017;23:2972–80.

    CAS  PubMed  Google Scholar 

  112. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32:590–9.

    CAS  PubMed  Google Scholar 

  113. Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, et al. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. Clin Cancer Res. 2019;25:6160–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  114. Nakajima TE, Kadowaki S, Minashi K, Nishina T, Yamanaka T, Hayashi Y, et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021;27:1029–36.

    CAS  PubMed  Google Scholar 

  115. Sasaki A, Nakamura Y, Togashi Y, Kuno H, Hojo H, Kageyama S, et al. Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer. 2020;23:893–903.

    CAS  PubMed  Google Scholar 

  116. Bagheri V, Abbaszadegan MR, Memar B, Motie MR, Asadi M, Mahmoudian RA, et al. Induction of T cell-mediated immune response by dendritic cells pulsed with mRNA of sphere-forming cells isolated from patients with gastric cancer. Life Sci. 2019;219:136–43.

    CAS  PubMed  Google Scholar 

  117. Zhu B, Sun Y, Wei X, Zhou H, Cao J, Li C, et al. Dendritic cell vaccine loaded with mg-7 antigen induces cytotoxic T lymphocyte responses against gastric cancer. J Healthc Eng. 2022;1:1964081.

    Google Scholar 

  118. Zhang W, Lu X, Cui P, Piao C, Xiao M, Liu X, et al. Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother. 2019;68:121–30.

    CAS  PubMed  Google Scholar 

  119. Long B, Qin L, Zhang B, Li Q, Wang L, Jiang X, et al. CAR T cell therapy for gastric cancer: potential and perspective (review). Int J Oncol. 2020;56:889–99.

    CAS  PubMed  Google Scholar 

  120. Luo F, Qian J, Yang J, Deng Y, Zheng X, Liu J, et al. Bifunctional alphaHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Res. 2016;26:850–3.

    PubMed  PubMed Central  Google Scholar 

  121. Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS ONE. 2018;13: e0198347.

    PubMed  PubMed Central  Google Scholar 

  122. Nakayama Y, Mimura K, Kua LF, Okayama H, Min AKT, Saito K, et al. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer. 2020;23:961–73.

    CAS  PubMed  Google Scholar 

  123. Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPalpha immune checkpoint. Immunity. 2020;52:742–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Shi M, Gu Y, Jin K, Fang H, Chen Y, Cao Y, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunol Immunother. 2021;70:1831–40.

    CAS  PubMed  Google Scholar 

  125. Ishikawa T, Okayama T, Sakamoto N, Ideno M, Oka K, Enoki T, et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. Int J Cancer. 2018;142:2599–609.

    CAS  PubMed  Google Scholar 

Download references

Funding

This paper was supported by Wu Jieping Medical Foundation Special Fund for Clinical Research (Grant No. 320.6750.2021-02-57).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, 450007, Henan, People’s Republic of China

    Xiaqing Xu, Wenxing Li & Meng He

  2. School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450002, Henan, People’s Republic of China

    Jiaxing Chen, Qian Liu & Wenfang Gao

  3. Department of Cancer Center, Nanyang First People’s Hospital, Nanyang, 473000, Henan, People’s Republic of China

    Chenlu Feng

Authors
  1. Xiaqing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiaxing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wenxing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chenlu Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenfang Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Meng He
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XX and JC were involved in the conceptualization and writing of the first draft. WL, CF, and MH contributed to the review and editing the draft. QL and WG assisted in the check and proofread the draft.

Corresponding author

Correspondence to Meng He.

Ethics declarations

Conflict of interest

The authors declare that they have no competing financial interests or personal relationships to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, X., Chen, J., Li, W. et al. Immunology and immunotherapy in gastric cancer. Clin Exp Med 23, 3189–3204 (2023). https://doi.org/10.1007/s10238-023-01104-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-023-01104-2

Keywords

Search

Navigation